NCT03520517 - Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 2, 2018

Primary Completion Date

October 8, 2018

Study Completion Date

October 8, 2018

Conditions

Amyotrophic Lateral SclerosisALSLou Gehrig DiseaseLou Gehrig's DiseaseLou-Gehrigs DiseaseMotor Neuron Disease, Amyotrophic Lateral Sclerosis

Interventions

DRUG

BHV-0223

BHV-0223, 40 mg BID

Trial Locations (5)

Neurosciences Institute, Neurology - Charlotte, Charlotte

Holy Cross Neuroscience Research Institute, Fort Lauderdale

Wesley Neurology Clinic, Cordova

Somnos/Neurology Associates Clinical Research, Lincoln

Texas Neurology, Dallas